Atrial natriuretic factor (1-28) (human, porcine) (TFA)

Atrial natriuretic factor (1-28) (human, porcine) TFA exhibits blood pressure lowering activity by increasing sodium and urine excretion. Atrial natriuretic factor (1-28) (human, porcine) TFA inhibits the release of pituitary adrenocorticotropic hormone (ACTH) and beta-endorphin through inhibition of pro-opiomelanocortin (POMC) expression. Atrial natriuretic factor (1-28) (human, porcine) TFA increases cGMP levels in RMIC cells with an IC50 of 1.2 nM[1][2][3].

Product Specifications

Product Name Alternative

Atrial natriuretic peptide (1-28) (TFA)

UNSPSC

12352209

Target

Endogenous Metabolite

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease

Purity

98.07

Solubility

H2O : ≥ 100 mg/mL

Smiles

O=C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CS)C(N[C@@H](CC1=CC=CC=C1)C(NCC(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CO)C(NCC(N[C@@H](CC(C)C)C(NCC(N[C@@H](CS)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC3=CC=C(C=C3)O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CO)N.OC(C(F)(F)F)=O.[x]

Molecular Formula

C127H205N45O39S3.xC2HF3O2

Molecular Weight

3080.46 (free base)

References & Citations

[1]B M Fontoura, et al. Atrial natriuretic factor receptors in cultured renomedullary interstitial cells. Am J Physiol. 1990 Apr;258 (4 Pt 1) :C692-9.|[2]T T Tan, et al. ANF (1-28) is a potent suppressor of pro-opiomelanocortin (POMC) mRNA but a weak inhibitor of beta EP-LI release from AtT-20 cells. J Endocrinol. 1994 Nov;143 (2) :R1-4.|[3]D M Pollock, et al. Beneficial effect of the ANF analog A68828 on recovery from ischemic acute renal failure. Ren Fail. 1992;14 (2) :141-6.